Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
Identifieur interne : 000593 ( Main/Corpus ); précédent : 000592; suivant : 000594Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
Auteurs : I. ShoulsonSource :
- Acta Neurologica Scandinavica [ 0001-6314 ] ; 1989-11.
English descriptors
- KwdEn :
Abstract
Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.
Url:
DOI: 10.1111/j.1600-0404.1989.tb01798.x
Links to Exploration step
ISTEX:79062544A2AE653E90A759BDAFC71EE384E96749Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name><affiliation><mods:affiliation>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:79062544A2AE653E90A759BDAFC71EE384E96749</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1111/j.1600-0404.1989.tb01798.x</idno><idno type="url">https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000593</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><author><name sortKey="Shoulson, I" sort="Shoulson, I" uniqKey="Shoulson I" first="I." last="Shoulson">I. Shoulson</name><affiliation><mods:affiliation>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Acta Neurologica Scandinavica</title><idno type="ISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11">1989-11</date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="171">171</biblScope><biblScope unit="page" to="175">175</biblScope></imprint><idno type="ISSN">0001-6314</idno></series><idno type="istex">79062544A2AE653E90A759BDAFC71EE384E96749</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01798.x</idno><idno type="ArticleID">ANE171</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0001-6314</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clinical trial</term><term>deprenyl</term><term>experimental therapeutics</term><term>protective therapy</term><term>tocopherol</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>I. Shoulson</name><affiliations><json:string>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>deprenyl</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>tocopherol</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trial</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>protective therapy</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>experimental therapeutics</value></json:item></subject><articleId><json:string>ANE171</json:string></articleId><language><json:string>eng</json:string></language><abstract>Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</abstract><qualityIndicators><score>6.034</score><pdfVersion>1.4</pdfVersion><pdfPageSize>486 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>6</keywordCount><abstractCharCount>1923</abstractCharCount><pdfWordCount>2534</pdfWordCount><pdfCharCount>16961</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>288</abstractWordCount></qualityIndicators><title>Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><genre><json:string>article</json:string></genre><host><volume>80</volume><publisherId><json:string>ANE</json:string></publisherId><pages><total>5</total><last>175</last><first>171</first></pages><issn><json:string>0001-6314</json:string></issn><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1600-0404</json:string></eissn><title>Acta Neurologica Scandinavica</title><doi><json:string>10.1111/(ISSN)1600-0404</json:string></doi></host><publicationDate>1989</publicationDate><copyrightDate>1989</copyrightDate><doi><json:string>10.1111/j.1600-0404.1989.tb01798.x</json:string></doi><id>79062544A2AE653E90A759BDAFC71EE384E96749</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1989</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title><author><persName><forename type="first">I.</forename><surname>Shoulson</surname></persName><note type="correspondence"><p>Correspondence: Address: Ira Shoulson, M.D. University of Rochester Department of Neurology 601 Elmwood Avenue, Box 673 Rochester, New York 14642 U.S.A.</p></note><affiliation>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</affiliation></author></analytic><monogr><title level="j">Acta Neurologica Scandinavica</title><idno type="pISSN">0001-6314</idno><idno type="eISSN">1600-0404</idno><idno type="DOI">10.1111/(ISSN)1600-0404</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1989-11"></date><biblScope unit="volume">80</biblScope><biblScope unit="supplement">s126</biblScope><biblScope unit="page" from="171">171</biblScope><biblScope unit="page" to="175">175</biblScope></imprint></monogr><idno type="istex">79062544A2AE653E90A759BDAFC71EE384E96749</idno><idno type="DOI">10.1111/j.1600-0404.1989.tb01798.x</idno><idno type="ArticleID">ANE171</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1989</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>deprenyl</term></item><item><term>tocopherol</term></item><item><term>clinical trial</term></item><item><term>protective therapy</term></item><item><term>experimental therapeutics</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1989-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/79062544A2AE653E90A759BDAFC71EE384E96749/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1600-0404</doi><issn type="print">0001-6314</issn><issn type="electronic">1600-0404</issn><idGroup><id type="product" value="ANE"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ACTA NEUROLOGICA SCANDINAVICA">Acta Neurologica Scandinavica</title></titleGroup></publicationMeta><publicationMeta level="part" position="11000"><doi origin="wiley">10.1111/ane.1989.80.issue-s126</doi><numberingGroup><numbering type="journalVolume" number="80">80</numbering><numbering type="supplement">s126</numbering></numberingGroup><coverDate startDate="1989-11">November 1989</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0017100" status="forIssue"><doi origin="wiley">10.1111/j.1600-0404.1989.tb01798.x</doi><idGroup><id type="unit" value="ANE171"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><eventGroup><event type="firstOnline" date="2009-01-29"></event><event type="publishedOnlineFinalForm" date="2009-01-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-14"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="171">171</numbering><numbering type="pageLast" number="175">175</numbering></numberingGroup><correspondenceTo>Address: Ira Shoulson, M.D. University of Rochester Department of Neurology 601 Elmwood Avenue, Box 673 Rochester, New York 14642 U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ANE.ANE171.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="referenceTotal" number="31"></count><count type="linksCrossRef" number="2"></count></countGroup><titleGroup><title type="main">Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>I.</givenNames><familyName>Shoulson</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="US"><unparsedAffiliation>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Parkinson's disease</keyword><keyword xml:id="k2">deprenyl</keyword><keyword xml:id="k3">tocopherol</keyword><keyword xml:id="k4">clinical trial</keyword><keyword xml:id="k5">protective therapy</keyword><keyword xml:id="k6">experimental therapeutics</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract– </b> DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)</title></titleInfo><name type="personal"><namePart type="given">I.</namePart><namePart type="family">Shoulson</namePart><affiliation>the Parkinson Study Group, Department of Neurology, University of Rochester Medical Center, Rochester, New York, U.S.A.</affiliation><description>Correspondence: Address: Ira Shoulson, M.D. University of Rochester Department of Neurology 601 Elmwood Avenue, Box 673 Rochester, New York 14642 U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1989-11</dateIssued><copyrightDate encoding="w3cdtf">1989</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">31</extent></physicalDescription><abstract lang="en">Abstract– DATATOP is a double‐blind, multi‐center, placebo‐controlled clinical trial aimed at slowing the decline of patients who are in the early stages of Parkinson's disease (PD). The specific aim is to determine whether or not chronic administration of deprenyl 10 mg per day and/or tocopherol 2000 IU per day to early, otherwise untreated PD patients will prolong the time until levodopa therapy is required to treat emerging disability. Deprenyl and tocopherol exert antioxidative effects through separate but complementary mechanisms of action. A 2 X 2 factorial design allocates eligible subjects to one of four treatment groups: 1) deprenyl alone, 2) tocopherol alone, 3) deprenyl plus tocopherol, or 4) placebo. Eligible subjects include early PD patients (illness duration less than 5 years and in stages I and II), aged 30 to 79, who are not taking or requiring any anti‐PD medications. The major response variable is the time period from randomization until the blinded investigator judges levodopa necessary to treat emerging parkinsonian disability. Randomization is stratified to ensure that treatment assignments are balanced for each blinded investigator. Cerebrospinal fluid is sampled just prior to randomization and one month after washout of experimental medications in order to help distinguish between symptomatic and protective effects of interventions. Based on pilot studies it is estimated that approximately 85 % of untreated PD patients will require levodopa within two years and a total sample size of 800 subjects will provide a 95 % likelihood for detecting a 10 %“survival'’difference between experimental medications and placebo. Between September 1987 and November 1988, 800 eligible subjects were enrolled in DATATOP by 34 investigators of the Parkinson Study Group, representing research centers in the United States and Canada. Primary analyses of DATATOP should be completed in 1991.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>deprenyl</topic><topic>tocopherol</topic><topic>clinical trial</topic><topic>protective therapy</topic><topic>experimental therapeutics</topic></subject><relatedItem type="host"><titleInfo><title>Acta Neurologica Scandinavica</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0001-6314</identifier><identifier type="eISSN">1600-0404</identifier><identifier type="DOI">10.1111/(ISSN)1600-0404</identifier><identifier type="PublisherID">ANE</identifier><part><date>1989</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>s126</number></detail><extent unit="pages"><start>171</start><end>175</end><total>5</total></extent></part></relatedItem><identifier type="istex">79062544A2AE653E90A759BDAFC71EE384E96749</identifier><identifier type="DOI">10.1111/j.1600-0404.1989.tb01798.x</identifier><identifier type="ArticleID">ANE171</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000593 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000593 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:79062544A2AE653E90A759BDAFC71EE384E96749
|texte= Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP)
}}
| This area was generated with Dilib version V0.6.23. |  |